![](/-/media/editorial/scrip/2024/06/sc2406_titans_of_pharma_2024_1200.jpg?rev=3f3b082c7b694da8a493a823e2c1c14f&w=350&hash=45BBF277DF407063ABB22BF05A8CB720)
Titans Of Pharma: J&J Back On Top For CEO Remuneration
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
![](/-/media/editorial/stock-images/diseases/musculardystrophywheelchairperson.jpg?rev=6052f443ad304f419dbdf1c1751a66d2&w=350&hash=7EA190110421E31C352DDCBDB59294EA)
New Promise, Looming Competition For DMD In China
With several new drugs progressing for the estimated 70,000 patients in China with DMD, a recent setback for Nippon Shinyaku's contender and progress for Chinese gene therapy developers are adding both uncertainty and likely competition in an untapped market with pressing medical need.
![](/-/media/editorial/scrip/2024/06/sc2406_parkinson_disease_1936960210_1074472160_1200-(002).jpg?rev=18cdeb32daa54073b9e66b1ccea9ee54&w=350&hash=5F69BBA7179E49455266BAEDE9CE5F87)
Bukwang Adds To Stacking Mid-Stage Failures In Parkinson's
Bukwang and subsidiary Contera have become the latest to fail to progress a novel Parkinson's therapy to late-stage trials after a Phase II miss, although several other Korean firms remain in the race for the challenging indication, albeit mainly in Phase I-II.
![](/-/media/editorial/scrip/2024/05/sc2404_discovery-versus-dealmaking_1955843626_2337256639_1200.jpg?rev=16a4b7383b3349d9a19a20840d2c3b54&w=350&hash=916C40785F1B3351069BB40D52D9B3A2)
Development Versus Dealmaking: How To Obtain A Blockbuster
Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.
![](/-/media/editorial/scrip/2024/05/sc2404_rapid-rise-or-slow-roll__2401154721_1200.jpg?rev=ed9019eaaef949529e163d3ffa9542d3&w=350&hash=62B98FCFE5F1A6B31754B22DE0FAD2FD)
Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?
Scrip analyzed data on top-selling drugs to see how long it takes to surpass $1bn in revenues and grow into $5bn and even $10bn brands.
![](/-/media/editorial/scrip/2024/05/sc2404_blockbusters-go-niche_1946107990_1200.jpg?rev=a6e0a80586dc4fddb9ef6005331acc73&w=350&hash=6CBEF83489B6E67944AB0CDDD8F0E67A)
Blockbusters By Indication: More Begets More
A Scrip analysis of the industry’s top-selling drugs examines the power of indication expansion to drive revenue growth.
![](/-/media/editorial/scrip/2024/05/sc2404_the-life-of-a-blockbuster_429078091_1200.jpg?rev=3875a0e42697425aa982958e27fc310c&w=350&hash=B3660F08E054D0D297B03733B0BF94C8)
The Life Of A Blockbuster
The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs to see which are forecast to make the most at peak and over a 14-year time horizon.
![](/-/media/editorial/scrip/2024/05/sc2405_savings_shutterstock_1174200262_1200x675.jpg?rev=6765dcdc237e4926abdf0649081d2980&w=350&hash=836803A9D32C3E33C438602DBC629FF2)
Hypertension To Mental Health Drugs: Indian Firms Supplied Bulk Of Rx Volume In US
Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.
![](/-/media/editorial/scrip/2024/04/sc2404_dollar_pill_210153328_1200.jpg?rev=44932621e9f443a0bb237d119d256adf&w=350&hash=A4ADAE101D84D5494E89855E8C83E325)
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
![](/-/media/editorial/stock-images/business/ipobutton_maximp_1009727707_1200.jpg?rev=8124cab18fb34bf2a126054888464a88&w=350&hash=1541BE39A76713438104C3DF49CEAE4E)
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
![](/-/media/editorial/stock-images/global-medicine-pills-map.jpg?rev=361ca3e99f684fd2aac004fd5e4a8185&w=350&hash=226C3A2863348DD0016D01F6B6981776)
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
![](/-/media/editorial/scrip/2023/01/sc2301_liver_1262047429_1200.jpg?rev=2cd4ba3d37a04548a2a7481c185ab910&w=350&hash=DA8399D45AADC584B2B837067146179D)
Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
![](/-/media/editorial/pink-sheet/2024/02/ps2402_green-and-purple-spirals_402687193-1200.jpg?rev=ae78cbc77966464bad1232bdf3b5e609&w=350&hash=98CB9D8DC6468FBD6972F589252AFF0C)
A Visual Trip Through The Psychedelic Pipeline
An infographic looking at the status and origins of 39 psychedelic drug development programs being pursued by 26 sponsors.
![](/-/media/candd/images/wegovy-injection_2386743011.jpg?rev=4314f0b2cffc4077b3851b7708085968&w=350&hash=79AC6DEF1488AB5C34B6CE038CFADCD8)
Weighty Matters: The Obesity Market Now… And In Years To Come
INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.
![](/-/media/editorial/stock-images/locations/londonskyline-1200-shutterstock_1501103324.jpg?rev=97c7e4eb83d1418da312853a21b8c3dc&w=350&hash=7CCA939843F8591F21A6A839D41897D4)
Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth
Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.
![](/-/media/editorial/buildings/corporate/e/lilly-blue-sky-1200-shutterstock_1846847821.jpg?rev=a1b2f0381c934a479f3b741a3ec896ae&w=350&hash=6D00A9BF437AC5B6F8E0CA217E212B0E)
Biopharma’s Winners And Losers Of 2023: Obesity Drugs Reshape Big Pharma
Novo Nordisk and Eli Lilly kickstarted an obesity drug revolution in 2023, just as investors cooled on biopharma’s vaccine saviors as the world looked to move on from COVID-19.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.